Target intelligence / Profile preview

Dynein axonemal heavy chain 12 (DNAH12)

Target
DNAH12
Molecular classification
Motor protein, Dynein family, Inner dynein arm (IDA) heavy chain
01

Overview

Dynein axonemal heavy chain 12 (DNAH12) is a large, mammalian-conserved inner dynein arm heavy chain motor protein expressed predominantly in the testes and ciliated tissues including lungs, trachea, and oviducts[1][3]. The protein comprises a N-terminal stem domain crucial for protein-protein interactions and a motor domain with ATPase activity that powers minus-end-directed microtubule movement, essential for sperm motility and flagellar assembly[1][2][3]. DNAH12 interacts with other axonemal dynein components, notably DNALI1 and DNAH1, forming a critical complex for flagellar development and axonemal integrity. Deficiency or mutations in DNAH12 disrupt proper recruitment of interacting components, impair sperm flagella structure, and can result in severe asthenoteratozoospermia or MMAF, manifesting primarily as male infertility but without classic PCD symptoms known for other dynein family members[1][3]. DNAH12 is predicted to lack the microtubule-binding domain present in other dynein heavy chains, marking its unique molecular features within the dynein superfamily[1].

Other names
DHC3DLP12DNAH12LDNAH7LDNAHC3DNHD2HDHC3HL19Dnahc3hdhc3FLJ40427FLJ44290Axonemal beta dynein heavy chain 12Ciliary dynein heavy chain 12Dynein heavy chain domain-containing protein 2axonemal dynein heavy chain isotype3dynein, axonemal, heavy polypeptide 12Dynein, heavy chain-5SPGF100
02

Mechanism of action

Not applicable (no drugs known to target this protein directly)

03

Biological functions

ATP hydrolysis and force generationSperm flagellar assembly and motilityMicrotubule-based movementMaintenance of axonemal structure and integrity
04

Disease associations

Male infertility (especially asthenoteratozoospermia and motile sperm defects)Multiple morphological abnormalities of the sperm flagella (MMAF)Primary ciliary dyskinesia (PCD; limited evidence for direct involvement)
05

Safety considerations

Potential therapeutic targeting is unknown; essential for sperm structure, so loss of function leads to infertility but no systemic safety data exists
06

Biomarkers

DNAH12 genetic variants are candidate biomarkers for male infertility, especially in MMAF and asthenoteratozoospermiaLoss/alteration of DNAH12 protein expression in spermatozoa may serve as a diagnostic marker for certain flagellar defects

Beyond the preview

Go deeper on Dynein axonemal heavy chain 12 (DNAH12).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dynein axonemal heavy chain 12 (DNAH12).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call